Casdatifan

Small molecule

Phase 3underway

Evidence outlook · registrational

Clear Cell Renal Cell Carcinoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-04.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Clear Cell Renal Cell Carcinoma
Phase 2 (1)
Other / comorbidity
NCT07397611 · Dana-Farber Cancer Institute
2026-03-09 – 2029-09-30 · Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma
What this study did
Phase 1/2 (2)
Clear Cell Renal Cell Carcinoma
NCT07227415 · Pfizer
2026-02-10 – 2028-11-01 · Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma
What this study did
Other / comorbidity
NCT07293351 · Bristol-Myers Squibb
2026-03-26 – 2031-11-26 · Advanced Renal Cell Carcinoma (RCC)
What this study did
Phase 1 (9)
Clear Cell Renal Cell Carcinoma
NCT07748988 · Vanderbilt-Ingram Cancer Center
2026-09-21 – 2031-01-01 · Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
What this study did
NCT05536141 · Arcus Biosciences, Inc.
2022-10-26 – 2029-03 · Clear Cell Renal Cell Carcinoma, Solid Tumors
What this study did
NCT07000149 · AstraZeneca
2025-07-28 – 2027-01-29 · Advanced Clear Cell Renal Cell Carcinoma
What this study did
NCT06191796 · Exelixis
2024-01-25 – 2025-05-12 · Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
What this study did
Other / comorbidity
NCT07751250 · Arcus Biosciences, Inc.
2026-08-14 – 2027-05 · Healthy Participants, Hepatic Impairment
What this study did
NCT07641881 · Arcus Biosciences, Inc.
2026-05-29 – 2026-08-07 · Healthy Participants
What this study did
NCT06919991 · Arcus Biosciences, Inc.
2025-05-02 – 2025-10-18 · Healthy Participants
What this study did
NCT05999513 · Arcus Biosciences, Inc.
2023-08-21 – 2023-10-31 · Healthy Participants
What this study did
NCT05117554 · Arcus Biosciences, Inc.
2021-11-09 – 2023-02-17 · Healthy Participants
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Clear Cell Renal Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Casdatifan: this drugPhase 3Small moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
Belzutifan (Welireg)
Approved(overall)
Small moleculeHIF-2alpha
not yet graded(overall)
No reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
DarlifarnibPhase 1Small moleculeFarnesyltransferasenot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
XmAb819Phase 1Multispecific antibodyENPP3 x CD3not yet gradedNo reviewed efficacy summary in this indication
CTX131DiscontinuedCell therapyCD70not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Casdatifan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Phase 1Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-29 · NCT07000149 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1Healthy Participants, Hepatic ImpairmentRecruiting
Est. primary completion 2027-05 · NCT07751250 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-11-02 · NCT07227415 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 2Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal CarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT07397611 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2028-04 · NCT07011719 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Phase 1Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2029-03 · NCT05536141 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Advanced Renal Cell Carcinoma (RCC)Recruiting
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 1Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2030-07-01 · NCT07748988 · CT.gov ↗
What to watch

See the full readout calendar ↗